XML 30 R19.htm IDEA: XBRL DOCUMENT
v3.5.0.2

License and Collaboration Agreements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract] |
License, Collaboration and Other Revenue | In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):
|  |  |  | Three months ended September 30, |  |  | Nine months ended September 30, |
Partner |  | Drug or Drug Candidate |  | 2016 |  |  | 2015 |  |  | 2016 |  |  | 2015 |
AstraZeneca AB |  | MOVANTIKTM and MOVANTIKTM fixed-dose combination program |  | $ | 3,000 |  |  | $ | 40,000 |  |  | $ | 31,000 |  |  | $ | 130,000 |
Roche |  | PEGASYS® and MIRCERA® |  |  | 1,929 |  |  |  | 3,212 |  |  |  | 5,771 |  |  |  | 9,619 |
Amgen, Inc. |  | Neulasta® |  |  | 1,250 |  |  |  | 1,250 |  |  |  | 3,750 |  |  |  | 3,750 |
Daiichi Sankyo Europe GmbH |  | ONZEALDTM (NKTR-102) |  |  | 216 |  |  |  | — |  |  |  | 3,474 |  |  |  | — |
Bayer Healthcare LLC |  | BAY41-6551 (Amikacin Inhale) |  |  | 357 |  |  |  | 357 |  |  |  | 1,072 |  |  |  | 1,562 |
Baxalta Incorporated |  | ADYNOVATETM |  |  | 336 |  |  |  | 409 |  |  |  | 648 |  |  |  | 607 |
Other |  |  |  |  | 1,285 |  |  |  | 1,247 |  |  |  | 5,114 |  |  |  | 3,885 |
License, collaboration and other revenue |  | $ | 8,373 |  |  | $ | 46,475 |  |  | $ | 50,829 |  |  | $ | 149,423 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration